Christine Blank
Contributing Editor Christine Blank is a freelance writer based in Florida.
Rite Aid, Albertsons Expand Naloxone Access
Rite Aid and Albertsons expand naloxone Access, hoping to curb the opioid epidemic.
The Top Six Ways Trump’s Policies Will Impact Pharmacies
The Top Six Ways Trump’s Policies Will Impact Pharmacies
How the new Trump administration will affect everything from the ACA to the FDA.
New Legislation Aims to Prohibit DIR Fees
Bills have been introduced in both the Senate and House that are aimed at stopping direct and indirect remuneration fees, assuming they are passed.
Popular asthma inhaler now expanded to kids
A leading asthma inhaler will now be available to additional younger asthma patients, after FDA approved Spiriva Respimat (Boehringer Ingelheim) for the long-term, once-daily maintenance treatment of asthma in people age 6 and older.
Psoriasis drug approved with boxed warning
A new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drug’s clinical trials.
Independent Pharmacy Sued Over Fentanyl Overdose Death
A pharmacy in Pennsylvania allowed a man to pick up his mother's prescription for fentanyl after being told not to allow it, with tragic results.
Muscular dystrophy drug launch halts after pricing concerns
Marathon Pharmaceuticals is temporarily pausing the launch of its drug to treat a rare form of muscular dystrophy (MD) after concerns over its $89,000 price tag.
New bladder cancer, kidney disease therapies available
FDA recently approved 2 new therapies: an expanded drug indication for locally advanced or metastatic urothelial carcinoma (mUC) and a treatment for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Major allergic reactions linked to common antiseptics
FDA is warning about rare but serious allergic reactions have from the widely-used skin antiseptic products containing chlorhexidine gluconate.
Diabetic patients challenge insulin makers
In the latest flap over the high cost of drugs, diabetes patients filed a class-action lawsuit against insulin makers.

Poll